A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 when Administered to Participants with Alzheimer's Disease and Vascular Pathology

Grants and Contracts Details

StatusActive
Effective start/end date2/16/2212/8/22

Funding

  • PPD Investigator Services LLC: $34,994.00